IsoPlexis Proteomic Product Suite for CAR-T Therapy

Application Note

IsoPlexis Proteomic Product Suite for CAR-T Therapy

Learn how IsoPlexis’ Functional Proteomics reveals unique secretomic signatures and insights into CAR-T therapy.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this Application Note we discuss:

Overcoming challenges in CAR-T therapy and antigen escape in Multiple Myeloma

Comparing subtle gene edits in NK cell therapies

Precision analytics in automated CAR-T manufacturing with single-cell proteomics

Preinfusion biomarkers for predicting clinical outcome in CAR-T cell treatment

App-Note_Proteomic-Product-Suite-for-CAR-T-Therapy_IsoPlexis-1

App-Note_Proteomic-Product-Suite-for-CAR-T-Therapy_IsoPlexis-2

App-Note_Proteomic-Product-Suite-for-CAR-T-Therapy_IsoPlexis-3

App-Note_Proteomic-Product-Suite-for-CAR-T-Therapy_IsoPlexis-4

A Deeper Look

More about this Application Note

Overcoming Challenges in CAR-T Therapy

Cell therapy relies on immune cells from patients or healthy donors, and in the case of allogeneic therapies, development and production are more complicated.

To ensure that these cell products are potent and effective, knowing how to engineer potency and durability throughout the development and bioprocessing stages is crucial.

Download this App Note to learn how IsoPlexis can help you achieve this faster.

Get the Application Note

Back to the Top